SCHEMBL4208264

SCHEMBL4208264

C[C@@H](N)c1ccc(N)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 1/20 0.59
MEN1 O00255 3/20 0.47
MAPT P10636 3/20 0.47
KMT2A Q03164 3/20 0.47
PDE2A O00408 1/20 0.46
ACHE P22303 1/20 0.43
ALDH1A1 P00352 8/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
POLB P06746 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
TDP1 Q9NUW8 5/20 0.40
CYP3A4 P08684 4/20 0.40
TP53 P04637 3/20 0.40
HIF1A Q16665 2/20 0.39
HTT P42858 2/20 0.39
GAA P10253 1/20 0.39
ALOX12 P18054 1/20 0.39
MAPK1 P28482 3/20 0.38
ALOX15 P16050 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL342044 1.00 ADRB2 (0.59) ADRB2MEN1MAPTKMT2APDE2A
SCHEMBL3555995 1.00 ADRB2 (0.59) ADRB2MEN1MAPTKMT2APDE2A
Hydrochloric Acid SCHEMBL6795220 0.97 ADRB2 (0.56) ADRB2MEN1MAPTKMT2APDE2A
Hydrochloric Acid SCHEMBL3175939 0.97 ADRB2 (0.56) ADRB2MEN1MAPTKMT2APDE2A
Hydrochloric Acid SCHEMBL6801092 0.97 ADRB2 (0.56) ADRB2MEN1MAPTKMT2APDE2A
SCHEMBL29225752 0.92 ALDH1A1 (0.55) ADRB2MEN1MAPTKMT2APDE2A
SCHEMBL29225750 0.92 ALDH1A1 (0.55) ADRB2MEN1MAPTKMT2APDE2A
SCHEMBL1314596 0.87 ADRB2 (0.72) ADRB2MAPTKMT2APDE2AALDH1A1
SCHEMBL28318549 0.86 ALDH1A1 (0.52) ADRB2MAPTPDE2AALDH1A1NPC1
SCHEMBL17540834 0.85 ADRB2 (0.70) ADRB2MEN1MAPTKMT2APDE2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112020357-B Salt of indazolyl-containing tricyclic derivative and crystal form thereof 上海翰森生物医药科技有限公司 2023-08-29 CN disclosed
WO-2020200161-A1 SALT OF INDAZOLYL-CONTAINING TRICYCLIC DERIVATIVE AND CRYSTAL FORM THEREOF 上海翰森生物医药科技有限公司 2020-10-08 WO disclosed
EP-3699179-A1 PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) 2020-08-26 EP disclosed
US-20200247815-A1 PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2020-08-06 US disclosed
WO-2019076336-A1 PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF 江苏豪森药业集团有限公司 2019-04-25 WO disclosed
WO-2016010402-A1 ORGANIC ELECTROLUMINESCENT DEVICE ROHM AND HAAS ELECTRONIC MATERIALS KOREA LTD. (KR) 2016-01-21 WO disclosed
WO-2011025565-A1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2011-03-03 WO disclosed
US-20100168070-A1 COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE HEINE NIKLAS 2010-07-01 US disclosed
US-20100168070-A1 COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE HEINE NIKLAS 2010-07-01 US disclosed
US-20100144681-A1 COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE BOEHRINGER INGELHEIM INTERNATION GMNB (DE) 2010-06-10 US disclosed
US-20100144681-A1 COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE BOEHRINGER INGELHEIM INTERNATION GMNB (DE) 2010-06-10 US disclosed
US-20090042867-A1 COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE FUCHS KLAUS 2009-02-12 US disclosed
US-20080293680-A1 Substituted Ethane-1,2-Diamines for the Treatment of Alzheimer's Disease II PETERS STEFAN 2008-11-27 US disclosed
US-20080293680-A1 Substituted Ethane-1,2-Diamines for the Treatment of Alzheimer's Disease II PETERS STEFAN 2008-11-27 US disclosed
WO-2008129380-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2008-10-30 WO disclosed
EP-1915352-A1 COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE Boehringer Ingelheim International GmbH (DE) 2008-04-30 EP disclosed
WO-2007017509-A1 COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-02-15 WO disclosed
WO-2007017511-A2 COMPOUNDS FOR TREATING ALZHEIMER'S DISEASE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-02-15 WO disclosed
WO-2007017510-A2 ISOPHTHALIC ACID DIAMIDES FOR TREATING ALZHEIMER'S DISEASE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-02-15 WO disclosed
WO-2007014946-A1 SUBSTITUTED ETHANE-1,2-DIAMINES FOR THE TREATMENT OF ALZHEIMER'S DISEASE II BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168070-A1 COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE PSEN1, PSEN2, ADORA3 ADRB2 142/4885MEN1 1676/4885MAPT 21/4885
US-20090042867-A1 COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE PSEN1, PSEN2, MAOB ADRB2 135/4885MEN1 1752/4885MAPT 18/4885
US-20200247815-A1 PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF MAPK1, MAPK11, MAPK14 ADRB2 3992/4885MEN1 904/4885MAPT 3727/4885
US-20100144681-A1 COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE PSEN1, PSEN2, ADORA3 ADRB2 139/4885MEN1 1798/4885MAPT 19/4885
US-20080293680-A1 Substituted Ethane-1,2-Diamines for the Treatment of Alzheimer's Disease II PSEN2, PSEN1, APP ADRB2 98/4885MEN1 883/4885MAPT 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.